Table III.
Survival rate according to genotype in rectal cancer.
| Genotype | OS
|
RFS
|
||||
|---|---|---|---|---|---|---|
| n (%) | Adjusted HRa (95% CI) | p-value | n (%) | Adjusted HRa (95% CI) | p-value | |
| hsa-mir-146aC>G | ||||||
| CC | 62 (36.7) | 1.000 (Ref.) | 61 (37.9) | 1.000 (Ref.) | ||
| GC | 84 (49.7) | 1.585 (0.718–3.501) | 0.257 | 78 (48.4) | 1.139 (0.558–2.324) | 0.723 |
| GG | 23 (13.6) | 0.638 (0.171–2.378) | 0.506 | 22 (13.7) | 0.799 (0.218–2.924) | 0.735 |
| CC | 62 (36.7) | 1.000 (Ref.) | 61 (37.9) | 1.000 (Ref.) | ||
| GC/GG | 107 (63.3) | 1.337 (0.618–2.893) | 0.463 | 100 (62.1) | 1.089 (0.540–2.196) | 0.813 |
| CC/GC | 146 (86.4) | 1.000 (Ref.) | 139 (86.3) | 1.000 (Ref.) | ||
| GG | 23 (13.6) | 0.476 (0.144–1.572) | 0.226 | 22 (13.7) | 0.733 (0.220–2.446) | 0.615 |
| hsa-mir-149C>T | ||||||
| TT | 82 (48.5) | 1.000 (Ref.) | 77 (47.8) | 1.000 (Ref.) | ||
| TC | 65 (38.5) | 1.094 (0.542–2.210) | 0.803 | 63 (39.1) | 1.136 (0.545–2.370) | 0.735 |
| CC | 22 (13.0) | 0.640 (0.212–1.930) | 0.430 | 21 (13.0) | 0.664 (0.234–1.885) | 0.444 |
| TT | 82 (48.5) | 1.000 (Ref.) | 77 (47.8) | 1.000 (Ref.) | ||
| TC/CC | 87 (51.5) | 0.951 (0.491–1.840) | 0.881 | 84 (52.2) | 0.977 (0.486–1.964) | 0.949 |
| TT/TC | 147 (87.0) | 1.000 (Ref.) | 140 (87.0) | 1.000 (Ref.) | ||
| CC | 22 (13.0) | 0.615 (0.213–1.777) | 0.372 | 21 (13.0) | 0.618 (0.237–1.615) | 0.329 |
| hsa-mir-196a2C>T | ||||||
| TT | 41 (24.3) | 1.000 (Ref.) | 39 (24.2) | 1.000 (Ref.) | ||
| TC | 81 (47.9) | 3.554 (1.296–9.747) | 0.014 | 78 (48.5) | 1.879 (0.767–4.603) | 0.170 |
| CC | 47 (27.8) | 2.089 (0.642–6.798) | 0.224 | 44 (27.3) | 0.997 (0.345–2.885) | 0.996 |
| TT | 41 (24.3) | 1.000 (Ref.) | 39 (24.2) | 1.000 (Ref.) | ||
| TC/CC | 128 (75.7) | 3.093 (1.139–8.399) | 0.028 | 122 (75.8) | 1.558 (0.647–3.749) | 0.325 |
| TT/TC | 122 (72.2) | 1.000 (Ref.) | 117 (72.7) | 1.000 (Ref.) | ||
| CC | 47 (27.8) | 0.780 (0.347–1.750) | 0.548 | 44 (27.3) | 0.620 (0.280–1.372) | 0.241 |
| hsa-mir- 499A>G | ||||||
| AA | 102 (60.4) | 1.000 (Ref.) | 98 (60.9) | 1.000 (Ref.) | ||
| AG | 62 (36.6) | 0.829 (0.409–1.680) | 0.605 | 58 (36.0) | 0.722 (0.345–1.513) | 0.391 |
| GG | 5 (3.0) | 1.206 (0.159–9.152) | 0.857 | 5 (3.1) | 1.085 (0.142–8.266) | 0.938 |
| AA | 102 (60.4) | 1.000 (Ref.) | 98 (60.9) | 1.000 (Ref.) | ||
| AG/GG | 67 (39.6) | 0.853 (0.430–1.691) | 0.650 | 63 (39.1) | 0.744 (0.364–1.524) | 0.422 |
| AA/AG | 164 (97.0) | 1.000 (Ref.) | 156 (96.9) | 1.000 (Ref.) | ||
| GG | 5 (3.0) | 1.268 (0.168–9.553) | 0.819 | 5 (3.1) | 1.208 (0.160–9.100) | 0.855 |
OS, overall survival; RFS, relapse-free survival; HR, hazard ratio.
a
Percentage of patients adjusted for age, gender, tumor site, differentiation, chemotherapy and stage.